Key facts
- This page summarizes Michael Robert Martin's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 06 Mar 2023, 15:28.
Michael Robert Martin - 02 Mar 2023 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)
- Reporting relationship
- Chief Business Officer
- Issuer ticker
- AUPH
- Reported as of
- 02 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 06 Mar 2023, 15:28:50 UTC
- Prior SEC filing
- 09 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Stephen Robertson, Attorney-in-Fact for Michael Robert Martin
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael Robert Martin filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 06 Mar 2023.
Change
- Previous filing in this sequence was filed on 09 Nov 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AUPH
transaction
Common Stock
Award
- Transaction value
- Shares
- +107,202
- Change %
- +71%
- Price
- Shares after
- 259,162
- Date
- 02 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents grant of Restricted Stock Units (RSUs) payable solely in common stock of the Issuer that vest in three (3) equal annual installments on the first, second and third anniversary of the grant date.
Footnote F2
Each RSU represents a contingent right to receive one share of the Issuer's common stock.
Footnote F3
The reporting person has reported prior awards of restricted stock units in Table II of Form 4. The total reported in Column 5 includes the 107,202 newly awarded RSUs, 62,448 RSUs previously reported in Table II, which vests in three (3) equal annual installments beginning March 2, 2022 (Prior RSUs), and 89,512 shares of common stock. On March 2, 2023, 20,816 of Prior RSUs vested and 41,632 of Prior RSUs remained unvested.